Genentech Invests $700M to Build First East Coast Manufacturing Facility in Holly Springs, NC
HOLLY SPRINGS, NC – Biotech leader Genentech, part of the Roche Group, has officially broken ground on its first East Coast manufacturing facility, marking a significant milestone for North Carolina’s fast-growing life sciences sector. The site represents an investment of more than $700 million, part of Roche’s broader $50 billion commitment to U.S. operations, according to Contract Pharma.
Facility Will Focus on Next-Generation Medicines
The new 65,000 m² plant will specialize in high-volume, efficient, and sustainable production of Genentech’s future pipeline of metabolic medicines, including next-generation treatments for obesity.
Roche Group CEO Thomas Schinecker highlighted the importance of the project, saying,
“I am proud to break ground on our new state-of-the-art manufacturing facility in North Carolina, which will support the production of our next-generation obesity treatments.”
Strengthening Global Supply Chain Resilience
The Holly Springs site is designed to integrate advanced automation and digital technologies, helping expand capacity while bolstering Roche’s global supply chain resilience. It will complement existing production facilities in Europe and Switzerland, ensuring more balanced worldwide coverage, the report noted.
Timeline and Job Creation
Construction is scheduled for completion by 2029, with the site fully operational soon after. Located on a 400,000 m² campus, the facility provides ample room for future expansion as demand grows.
Once complete, the project is expected to create 1,900 new jobs, making it one of the largest biotech investments in North Carolina to date.
A Holly Springs official welcomed the groundbreaking, noting,
“This project not only brings thousands of jobs but positions our community at the forefront of life-saving medical innovation.”
North Carolina’s Biotech Boom
Analysts say the investment reinforces North Carolina’s position as a national leader in biotechnology and biomanufacturing. With strong research universities, a skilled workforce, and robust infrastructure, the state continues to attract global pharmaceutical companies seeking U.S. expansion.
Industry observers point out that Genentech’s decision cements the Triangle region as a hub for next-generation drug development and large-scale pharmaceutical production, according to Contract Pharma’s coverage.
Do you think North Carolina’s biotech sector will continue to accelerate with projects like Genentech’s Holly Springs facility? Share your thoughts in the comments and join the discussion at SaludaStandard-Sentinel.com.
